Noxa upregulation is associated with apoptosis of chronic lymphocytic leukemia cells induced by hyperforin but not flavopiridol
Chronic lymphocytic leukemia (CLL) is characterized by the accumulation of a CD5
þ B-lymphocyte clone resulting mainly from apoptosis deficiency. On account of the low response rate of the patients to chemotherapy, new therapeutic strategies based on apoptosis inducers including plant-derived compounds are under investigation (see Kolb et al. 1 for review). Flavopiridol, a semisynthetic flavonoid, is a potent inducer of CLL cell apoptosis in vitro, and a promising phase II clinical trial was recently reported. 2 The effect of flavopiridol is p53-independent and involves caspase-3 activation through the mitochondrial pathway and the downregulation of antiapoptotic proteins, notably Mcl-1. This member of the Bcl-2 family seems to be crucial in CLL, because its high expression levels are related to apoptosis resistance in vitro and to chemoresistance in vivo. 3 Hyperforin, a natural phloroglucinol, is another inducer of CLL cell apoptosis 4 that exhibits antiangiogenic properties and impairs transporter activities involved in multidrug resistance (see Quiney et al. 5 for review). Like flavopiridol, hyperforin acts through the mitochondrial caspase-dependent pathway of apoptosis, but decreases moderately Mcl-1 expression. However, the exact mechanisms whereby hyperforin and flavopiridol lead to the release of apoptogenic factors from mitochondria are not fully understood.
Noxa is a proapoptotic BH3-only member of the Bcl-2 family, which binds specifically Mcl-1 (see Willis and Adam 6 for review). When its BH3 domain inserts within the hydrophobic groove of Mcl-1, this displaces Mcl-1/Bak interaction, resulting in Bak freeing that leads to mitochondrial membrane permeabilization and finally to caspase activation. Recently, it was reported that Noxa expression levels are inversely related to CLL cell survival capacity. 7 Here, we addressed the question of the possible role of Noxa in the apoptosis of CLL cells induced in vitro by hyperforin or flavopiridol. Peripheral blood samples of 12 untreated CLL patients (stage A, according to Binet's classification) were obtained from the Hematology Department of Hô tel-Dieu hospital (Paris, France) after written informed consent, in accordance with the revised Helsinki protocol. Diagnosis was established according to the standard clinical criteria and to the International Workshop on CLL. The leukemic B-cells were purified (X95%) and immediately cultured as described previously. 8 Chronic lymphocytic leukemia cells were induced to apoptosis by treatment for 18 h in culture with either 1 mM flavopiridol (a gift from Aventis Pharmaceuticals, Bridgewater, NJ, USA) or 10 mg/ml (18 mM) hyperforin (purified and kindly provided by Dr JD Fourneron, Faculté de Pharmacie, Marseille, France). These experimental conditions were previously demonstrated to allow optimal apoptosis induction (notably DNA fragmentation, dissipation of the mitochondrial transmembrane potential and caspase-3 activation). 4, 8 Noxa expression was analyzed by western blotting from equal amounts of cell lysates (30-50 mg of proteins in SDS-reducing buffer), as described previously. 8 Two mAb against Noxa were used: IMG-249 from Imgenex (Clinisciences, Montrouge, France) and clone 6D619 from the US Biological (Euromedex, Mundolsheim, France). Caspase-dependent PARP-1 cleavage was evaluated simultaneously as a control of apoptosis. Expression of Mcl-1 and Bcl-2 was also analyzed, as well as two proteins, which are constitutively overexpressed in CLL cells and downregulated upon flavopiridol and hyperforin-triggered apoptosis: the inducible NO synthase that produces the antiapoptotic NO, and p27kip1 that is cleaved by caspases into a p23 fragment. 4, 8 Figure 1 shows that Noxa was expressed at low levels by CLL cells from eight patients (1) (2) (3) (4) (5) (6) (7) (8) . In all cases, hyperforin treatment resulted in a strong increase of Noxa expression and this effect was accompanied with stimulation of PARP cleavage (and p27 cleavage in some cases), as compared to untreated controls. In contrast, flavopiridol treatment, which also induced PARP and p27 cleavages, did not result in stimulation of Noxa expression; this latter was even decreased, likely due to the well-known inhibition of protein synthesis by the flavonoid, as revealed by a reduction in b-actin band intensity. Mcl-1 expression was strongly inhibited by flavopiridol, but occasionally by hyperforin. Regarding Bcl-2, the apparition of a cleaved fragment was observed especially after flavopiridol treatment. As expected, inducible NO synthase downregulation was induced by both compounds. The patient-dependent effects on Mcl-1, Bcl-2 and p27 were in accordance with previous data. 4, 8 Similar results were observed with four other patients (9) (10) (11) (12) . Indeed, in all 12 patients, the ratio of Noxa/actin band intensities increased after hyperforin treatment as compared to untreated controls (Figure 2a ). This increase ranged from 2.9-fold (patient 4) to 40.3-fold (patient 2). The effect of hyperforin on Noxa/actin ratio was highly significant, whereas this ratio did not change upon flavopiridol exposure (Figure 2b) .
Our results show for the first time that the upregulation of the proapoptotic protein Noxa is associated with CLL cell apoptosis induced by the natural phloroglucinol hyperforin but not by flavopiridol, another plant-derived compound. Recently, Noxa upregulation has been demonstrated to mediate apoptosis triggered by the proteasome inhibitor bortezomib in melanoma and two B-cell malignancies, multiple myeloma and mantle cell lymphoma 9, 10 and to be involved in bortezomib-elicited apoptosis of CLL cells. 7 Similarly, histone deacetylase inhibitors were found to induce CLL cell apoptosis through Noxa Figure 1 , and those obtained with four additional patients (9-12) were quantified with the NIH Image 1.62b software, and the Noxa/actin ratios were calculated. (a) Analysis for each of the 12 patients of the Noxa/actin ratio in CLL cells after treatment for 18 h with 1 mM flavopiridol (F) or 10 mg/ml hyperforin (H) and in untreated controls (C). (b) Statistical analysis using the paired t-test, providing a P-value of 0.17 for flavopiridol (NS, not significant) and a highly significant P-value for hyperforin. CLL, chronic lymphocytic leukemia.
Letters to the Editor upregulation. 11 Noxa induction was suggested to be transcriptionally regulated in melanoma cells. 9 Although the mechanisms controlling Noxa gene expression are not fully defined (see Smit et al. 7 for discussion), they appear to be p53-independent in malignant B-cells. 9, 10 The protein Noxa induced by either bortezomib or histone deacetylase inhibitors was actually found to bind Mcl-1 in CLL cells. 7, 11 Thus, as Noxa is known to displace Mcl-1/Bak interaction, its upregulation could be a major mechanism by which hyperforin triggers the mitochondrial pathway of caspase activation in CLL cells. Indeed, only marginal effects of the phloroglucinol on Mcl-1 or Bcl-2 were detected here; in addition, Mcl-1 cleavage seems rather a secondary mechanism inasmuch as it was previously found to be caspase-dependent. 4 Our observation that flavopiridol did not stimulate Noxa expression indicates that the flavonoid does not act through the same mechanism as hyperforin or other apoptosis inducers in CLL cells. The strong inhibition of Mcl-1 expression by flavopiridol, as a result of either protein degradation or transcriptional inhibition, may be sufficient to allow a sustained Bak activity, together with convergent downregulation of other antiapoptotic proteins. 4, 8 Moreover, the effects of certain apoptosis inducers could involve proapoptotic Bcl-2 familly members distinct from Noxa and Bak, such as Bak or the BH3-only Puma and Bim. 11 Finally, our results favor the concept that hyperforin and agents having the capacity to induce or mimic Noxa represent a novel attractive therapeutic strategy for CLL, as recently suggested. 12 Diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) are the two most commonly diagnosed subtypes of non-Hodgkin's lymphoma (NHL) in the United States.
1 Both diseases show variable progression, and identifying prognostic markers applicable in a clinical setting could greatly improve patient management. Established adverse prognostic factors in DLBCL as delineated in the International Prognostic Factor Index (IPI) include older age, higher stage, poor performance score, extranodal involvement and above normal lactate dehydrogenase. For FL, adverse prognostic factors are combined in the Follicular Lymphoma International Prognostic Index and include older age, higher stage, lower hemoglobin level, more nodal areas and above normal lactate dehydrogenase. As both IPI and Follicular Lymphoma International Prognostic Index predict risk incompletely, it is thought that molecular characteristics of the tumor and its microenvironment may improve predicting DLBCL and FL survival. Notably, recent gene expression studies suggest a molecular profile of DLBCL with poorer survival. 2 New prognostic markers for FL have also been suggested, 3 but none have yet been translated to the clinical setting. Evaluating host germline genetic variability offers another promising approach for refining prognosis of DLBCL and FL.
